FDA approves another GSK, Theravance lung drug

(Reuters) – The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's new lung drug for treatment of chronic obstructive pulmonary disease (COPD), commonly known as smoker's lung. However, the inhaled treatment, Anoro Ellipta, will carry a warning that one of its components increase the risk of asthma-related death, FDA said in a statement released on its website. (http://link.reuters.com/kep55v) Anoro Ellipta was developed along with U.S. partner Theravance Inc, in which Glaxo owns a 27 percent stake.